Associations of brain‐derived neurotrophic factor rs6265 polymorphism and cognitive function in breast cancer survivors from a cross‐sectional study
Cancer Medicine · 2024
DOI: 10.1002/cam4.6975 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Taichi Goto und 7 weiteren Autor:innen. Beteiligte Einrichtung: Symptoms Biology Unit, Division of Intramural Research, National Institute of Nursing Research, National Institutes of Health, Bethesda, Maryland, US…. Hauptthemen laut MEDLINE: Breast Neoplasms, Cancer Survivors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINR NIH HHS, Ohio State University, National Institute of Nursing Research.
Abstract (Originalsprache)
Background
Breast cancer survivors (BCS) often complain of cancer‐related cognitive impairment (CRCI) during and even months after completing primary cancer treatments, particularly chemotherapy. The etiology of CRCI is unknown, but associations of CRCI with germline genetic polymorphisms have been reported, including Brain‐Derived Neurotrophic Factor (BDNF) rs6265 polymorphism. The current study investigated the associations of specific BDNF rs6265 with CRCI.
Methods
Cancer‐related cognitive impairment was assessed using subjective reports of cognitive symptoms (the version 1.0, 8‐item short‐forms of the Patient‐Reported Outcomes Measurement Information System®) and computerized objective cognitive function scores (CANTAB®). BDNF rs6265 genotypes were determined from buccal swabs. The associations of specific BDNF rs6265 with CRCI were examined by either one‐way analysis of variance or the Kruskal–Wallis test followed by post hoc tests and rank‐based regression analysis.
Results
We examined 356 female BCS. The mean (SD) age was 55.6 (9.8) years old, the median (IQR) years since cancer diagnosis were 4.0 (6.0), and 331 (92.7%) were self‐described as White. BCS carrying the Met/Met genotype showed poorer results on ‘visual episodic memory and new learning’ and ‘spatial working memory and executive function.’ This relationship was observed regardless of prior chemotherapy.
Conclusion
Our findings suggest that carrying the BDNF rs6265 Met/Met genotype increases the risk for CRCI in BCS. These results are foundational in nature and provide important information to identify mechanisms underpinning CRCI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Symptoms Biology Unit, Division of Intramural Research, National Institute of Nursing Research, National Institutes of Health, Bethesda, Maryland, USA.
- Department of Biostatistics, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
- Indiana University School of Nursing, Indianapolis, Indiana, USA.
- The Ohio State University College of Nursing, Columbus, Ohio, USA.
ORCID-Profile: Taichi Goto, Leorey N Saligan, Diane Von Ah
Förderung
- NINR NIH HHS
- Ohio State University
- National Institute of Nursing Research
- Indiana University
Zitieren
APA
Goto, T., Saligan, L. N., Li, X., Xiang, L., Kwiat, C., Nguyen, C., Crouch, A., & Von Ah, D. (2024). Associations of brain‐derived neurotrophic factor rs6265 polymorphism and cognitive function in breast cancer survivors from a cross‐sectional study. Cancer Medicine. https://doi.org/10.1002/cam4.6975
Vancouver
Goto T, Saligan LN, Li X, Xiang L, Kwiat C, Nguyen C, et al. Associations of brain‐derived neurotrophic factor rs6265 polymorphism and cognitive function in breast cancer survivors from a cross‐sectional study. Cancer Medicine. 2024. doi:10.1002/cam4.6975
BibTeX
@article{Goto2024,
author = {Goto, Taichi and Saligan, Leorey N and Li, Xiaobai and Xiang, Lichen and Kwiat, Catherine and Nguyen, Christopher and Crouch, Adele and Von Ah, Diane},
title = {Associations of brain‐derived neurotrophic factor rs6265 polymorphism and cognitive function in breast cancer survivors from a cross‐sectional study},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.6975}
}
EUVIMED